

Expansion of Incannex™ Cannabinoid Oil Sales Program

Highlights:

- Impression places a purchase order for 3000 bottles of cannabinoid oils to be made available for sale under the Australian Special Access Scheme
- Three new cannabinoid products called Nutralesic, Inflammex and Releafia have been introduced to Impression's product mix, designed for greatest patient need
- Patients will continue to be acquired in conjunction with Cannvalate Pty Ltd, which is the largest distributor of medicinal cannabis products in Australia
- Cannvalate exercises second tranche of IHL options, making it a major shareholder of IHL.

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company'), undertaking clinical trials to develop four unique medicinal cannabis products, owner of Incannex™ cannabinoid oils and oral devices manufacturer, is pleased to announce that it has placed a significant purchase order for a range of new cannabinoid products.

An initial order of 3000 units has been placed with a wholesale manufacturer of medicinal cannabis oils, which has sufficient capacity to provide IHL surety of ongoing supply. The Incannex™ branded cannabinoid oils will be made available for sale to patients under the Australian Special Access Scheme ('SAS') for unregistered therapeutic goods.

The new products have been designed for the greatest possible patient coverage based on existing market dynamics and patient need. A second purchase is planned to be lodged shortly for another two products, including a soft gel capsule designed primarily for elderly patients who are prescribed Cannabidiol ('CBD').



Caption: Three new brands contain varying ratios of CBD, THC and other cannabinoids, called Nutralesic, Inflammex and Releafia

Impression has previously outlined that it had sourced over 1000 patients for its CBD-100 isolate product. The new brands open new avenues for sales as the Company now has a product suite that covers the majority of the addressable market for legal cannabinoid products in Australia. Not only will these products facilitate increased sales, but they will enable IHL to assess patient feedback to refine future products.

Impression has also expanded to its strategic relationship with Cannvalate to accelerate patient acquisition. Cannvalate is the largest distributor of medicinal cannabis products in Australia, and was co-founded by Dr Sud Agarwal, who is Chief Medical Officer and a director of Impression.

Following the expansion of the cannabinoid oil sales program, Cannvalate notified Impression of its intention to exercise its second tranche of stock options in IHL, which will make it a major long-term shareholder of Impression. An Appendix 2C reflecting the option exercise will be released when the shares are issued.

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited (IHL.ASX) is a first-in-class innovator and developer of a diversified mix of medicinal cannabis pharmaceutical products for global export potential. The Company is currently undertaking clinical programs to develop 4 uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury/Concussion, Temporomandibular Joint Disorder and Periodontitis (Gum Disease).

Each indication represents major global markets with significant yearly sales. 3 of the 4 indications currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Impression's chosen therapeutic areas and IHL has a strong patent filing strategy as it develops its products in conjunction with its medical advisory board of global key opinion leaders.

Further to its clinical programs, Impression also has its Australian licenses in place to import, export and distribute medicinal cannabis products and has launched a line of EU GMP approved CBD oil products under the brand, "INCANNEX". The INCANNEX cannabis-based oils are sold under Impression's product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia.

Yielding growing revenues to Impression is its customised oral devices manufacturing business. The oral devices division delivers high-quality products both direct to the consumer and via a growing B2B preferred practitioner network of dentists.

Investors: investors@impression.healthcare

Website: www.impression.healthcare